Gilead Believes Increasing Reports Of HCV Cures Will Reduce Payer Pushback On Sovaldi

Instant blockbuster Sovaldi continued the strongest drug launch in industry history, bringing in nearly $3.5 billion in net sales during the second quarter. But pricing pushback continues from payers in both the U.S. and Europe.